Tools

LEADER 03482cam 2200553 i 4500

001 ssj0002453227;

003 WaSeSS;

005 20250212121027.0;

006 m d ;

007 cr n ;

008 201204s2021 nyua sb 001 0 eng d;

010 a| 2020054438;

020 a| 9780197512883q| (hardback);

020 a| 9780197512876q| (paperback);

020 z| 9780197512906q| (epub);

020 z| 9780197512913q| (online);

035 a| (WaSeSS)ssj0002453227;

042 a| pcc;

049 a| EREEa| NEHH;

050 00 a| RA412.3b| .N48 2021;

060 00 a| QV 736 AA1;

082 00 a| 368.38/242| 23;

100 1 a| Neumann, Peter J.,d| 1961-=| ^A870142;

245 14 a| The right priceh| [electronic resource] :b| a value-based prescription for drug costs /c| Peter J. Neumann, Joshua T. Cohen, and Daniel A. Ollendorf.;

260 a| New York, NY :b| Oxford University Press,c| [2021];

300 a| xv, 255 pages :b| illustrations ;c| 24 cm;

504 a| Includes bibliographical references and index.;

505 0 a| The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.;

506 a| Available only to authorized users.;

520 a| The pharmaceutical industry and its pricing methods provide an inviting target, easy to disparage and caricature. Even after accounting for discounts and rebates, average prices of leading brand-name drugs in the US are two to four times higher than they are in Canada, Japan, and many European countries. US per capita spending on prescription drugs is more than twice the level in the United Kingdom. Prices for most new cancer drugs now exceed $100,000 per patient per year of treatment, despite the fact that many of these treatments seem to offer modest gains in life expectancy or lack such evidence at all. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million dollar price tags, the need for sensible drug pricing and coverage policies will intensify.;

538 a| Mode of access: World Wide Web;

650 12 a| Prescription Fees=| ^A952377;

650 22 a| Drug Costs=| ^A1004885;

650 22 a| Prescription Drugsx| economics=| ^A1195285;

651 2 a| United States=| ^A965939;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Cohen, Joshua T.?| UNAUTHORIZED;

700 1 a| Ollendorf, Daniel A.?| UNAUTHORIZED;

710 2 a| Oxford University Press.=| ^A636469;

856 40 z| Full text available from Oxford Scholarship Onlineu| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Facademic.oup.com%2Fbook%2F39397;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 5718722;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5718722-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 9/21/2021x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5718722-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 9/21/2021x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5718722-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 9/21/2021x| EBOOKz| JERESOURCE;

The right price a value-based prescription for drug costs / Peter J. Neumann, Joshua T. Cohen, and Daniel A. Ollendorf.

Author/creator	Neumann, Peter J., 1961-
Other author	Cohen, Joshua T.
Other author	Ollendorf, Daniel A.
Other author	Oxford University Press.
Format	Electronic
Publication Info	New York, NY : Oxford University Press, [2021]
Description	xv, 255 pages : illustrations ; 24 cm
Supplemental Content	Full text available from Oxford Scholarship Online
Subjects	Prescription Fees Drug Costs Prescription Drugs--economics. United States

Contents	The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.
Abstract	The pharmaceutical industry and its pricing methods provide an inviting target, easy to disparage and caricature. Even after accounting for discounts and rebates, average prices of leading brand-name drugs in the US are two to four times higher than they are in Canada, Japan, and many European countries. US per capita spending on prescription drugs is more than twice the level in the United Kingdom. Prices for most new cancer drugs now exceed $100,000 per patient per year of treatment, despite the fact that many of these treatments seem to offer modest gains in life expectancy or lack such evidence at all. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million dollar price tags, the need for sensible drug pricing and coverage policies will intensify.
Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
LCCN	2020054438
ISBN	9780197512883 (hardback)
ISBN	9780197512876 (paperback)
ISBN	(epub)
ISBN	(online)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

The right price a value-based prescription for drug costs / Peter J. Neumann, Joshua T. Cohen, and Daniel A. Ollendorf.

Click here for more information about this title

Availability